Abstract:The advent of biological therapy to treat many conditions, including autoimmune diseases, asthma, and even cancer, has changed the prognosis of millions of patients, decreasing morbidity and mortality and increasing quality of life. 1 1 Molinelli E, Campanati A, Ganzetti G, Offidani A. Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts. Curr Drug Saf. 2016;11(1):35-43. https://dx.doi.org/10.2174/1574886310666151014115127 https://dx.doi.org/10.2174/1574886310666... However, because of their mechanism of action, biological therapy can increase the risk of some infections, including tuberculosis. 2 2 Dobler CC. Biologic Agents and Tuberculosis. Microbiol Spectr. 2016;4(6):10.1128/microbiolspec.TNMI7-0026-2016. https://dx.doi.org/10.1128/microbiolspec.TNMI7-0026-2016 https://dx.doi.org/10.1128/microbiolspec... Latent tuberculosis infection (LTBI), or tuberculosis infection (TBI), as defined in the original article published by Sultana et al. 3 3 Sultana A, Migliori GB, D`Ambrosio L, García-García JM, Silva DR, Rendon LA, et al. Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent. J Bras Pneumol. 2024;50(4):e20240082. https://dx.doi.org/10.36416/1806-3756/e20240082 https://dx.doi.org/10.36416/1806-3756/e2... in this issue of the Journal, has a risk of reactivation increased by almost 30 times in patients using TNF-α inhibitors. 2 2 Dobler CC. Biologic Agents and Tuberculosis. Microbiol Spectr. 2016;4(6):10.1128/microbiolspec.TNMI7-0026-2016. https://dx.doi.org/10.1128/microbiolspec.TNMI7-0026-2016 https://dx.doi.org/10.1128/microbiolspec... This happens because such inhibitors block one of the most important cytokines responsible for the integrity of the tuberculous granuloma. 4 4 Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?. Clin Infect Dis. 2005;41 Suppl 3:S199-S203. https://dx.doi.org/10.1086/429998 https://dx.doi.org/10.1086/429998... However, it is still unclear whether biological therapy with other agents are associated or not with the risk of turning LTBI into active tuberculosis. 5 5 Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023;82(6):742-753. https://dx.doi.org/10.1136/ard-2022-223335 https://dx.doi.org/10.1136/ard-2022-2233... Additionally, clinical practice is largely heterogeneous, given different scenarios and tuberculosis burdens, which hinders the generalization of guidelines. Sultana et al. 3 3 Sultana A, Migliori GB, D`Ambrosio L, García-García JM, Silva DR, Rendon LA, et al. Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent. J Bras Pneumol. 2024;50(4):e20240082. https://dx.doi.org/10.36416/1806-3756/e20240082 https://dx.doi.org/10.36416/1806-3756/e2... bring a very interesting and timely topic by describing the different clinical practices regarding the approach to TBI worldwide and by evaluating if they are in line with their respective national or international guidelines. In that study, 3 3 Sultana A, Migliori GB, D`Ambrosio L, García-García JM, Silva DR, Rendon LA, et al. Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent. J Bras Pneumol. 2024;50(4):e20240082. https://dx.doi.org/10.36416/1806-3756/e20240082 https://dx.doi.org/10.36416/1806-3756/e2... 163 responders in 27 countries completed the survey. According to the authors, "TBI screening rates in patients treated with TNF-α inhibitors were high, especially for older TNF-α inhibitors. Most participants supported TBI screening in patients treated with B- or T-cell inhibitors but not in those treated with interleukin inhibitors. -Abstract Truncated-

S1498 Prevalence and Outcomes of Active and Latent Tuberculosis Among Patients With Inflammatory Bowel Disease (IBD) in an Endemic Region

P1111 Prevalence and risk factors for active tuberculosis in Tunisian IBD patients

Demographic, Clinical, Radiological, and Surgical Outcome of Patients with Intestinal Tuberculosis: A Single-Center Retrospective Study

P040 Latent Tuberculosis Infection In A Patient With A Negative Interferon Gamma Release Assay Prior to Biologic Initiation for Crohn's Disease

P502 Different Presentation of Tuberculosis Associated with Anti-Tnf Therapy among Patients with Inflammatory Bowel Disease in Endemic Area: Observation from China

Altered Intestinal Microbiota and Fecal Metabolites in Patients with Latent and Active Pulmonary Tuberculosis

Performance of Interferon-gamma Release Assay for Tuberculosis Screening in Inflammatory Bowel Disease Patients

Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries

Risk of tuberculosis with anti-TNF therapy in Indian patients with inflammatory bowel disease despite negative screening

Challenges in screening for latent tuberculosis in inflammatory bowel disease prior to biologic treatment: a UK cohort study

P568 Does Infliximab Therapy Increase Incidence of Tuberculosis in Patients with Inflammatory Bowel Disease in an Endemic Area: a Nationwide Study from China

Investigation on status quo of tuberculosis screening in 1711 patients with inflammatory bowel diseases before infliximab therapy in China

The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy

Screening for Latent Tuberculosis Infection in Solid Organ transplant recipients to predict active disease: a systematic review and meta-analysis of diagnostic studies

Tuberculosis Screening Using IGRA and Chest Computed Tomography in Patients with Inflammatory Bowel Disease: A Retrospective Study.

Abdominal tuberculosis in a tertiary care centre in Saudi Arabia

P016 IMPROVING TUBERCULOSIS RE SCREENING IN INFLAMMATORY BOWEL DISEASE PATIENTS RECEIVING BIOLOGIC THERAPY: A SINGLE CENTER QUALITY IMPROVEMENT INITIATIVE.

Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region

IDDF2018-ABS-0061 Risk of Tuberculosis in Inflammatory Bowel Disease and Other Immune-Mediated Diseases on Biological Therapy: a Population-Based Study in Hong Kong

Latent tuberculosis infection and biologic agents other than TNF-α inhibitors: "over-screening and over-treatment?"

Progress on Diagnosis and Treatment of Latent Tuberculosis Infection